Related Experiment Video
Updated: Nov 14, 2025
10:02
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
2.2K
Putting Proteomics Into Immunotherapy for Glioblastoma
Liangyu Chen1, Di Qin1, Xinyu Guo1
1Department of Proteomics, Tianjin Enterprise Key Laboratory of Clinical Multi-omics, Tianjin, China.
Frontiers in Immunology
|March 12, 2021
Summary
Proteomics advances, including unicellular analysis, offer new ways to understand glioblastoma complexity and immunosuppression. This enables precise tumor subtyping and biomarker discovery for improved immunotherapy strategies.
Area of Science:
- Neuro-oncology
- Cancer Proteomics
- Immunotherapy
Background:
- Glioblastoma presents a complex, immunosuppressive microenvironment hindering subtype classification and treatment.
- Current glioblastoma treatments are largely ineffective due to tumor heterogeneity and location.
- Immunotherapy shows promise for other cancers but faces challenges in glioma treatment.
Purpose of the Study:
- To review the application of proteomics strategies in advancing immunotherapy for glioblastoma.
- To highlight how proteomics can overcome challenges in glioblastoma subtype classification and treatment.
Main Methods:
- High-throughput liquid chromatography-mass spectrometry (LC-MS/MS) for protein identification and quantification.
- Unicellular proteomics for analyzing microenvironment and heterogeneity.
- Review of advanced proteomic studies on various immunotherapy approaches for glioma.
Main Results:
- Proteomics enables detailed protein mapping to elucidate glioblastoma mechanisms.
- Unicellular proteomics can characterize the tumor microenvironment and heterogeneity.
- Large-scale proteomic data facilitates precise tumor subtyping and biomarker identification.
Conclusions:
- Proteomics offers powerful tools to address glioblastoma heterogeneity and immunosuppression.
- Application of proteomics in immunotherapy research can accelerate the development of effective glioblastoma treatments.
- Proteomics is crucial for advancing immunotherapy, including monoclonal antibodies, oncolytic viruses, DC vaccines, and CAR T cells for glioma.
